GlassScriptPhysician profile
Vijay K Sharma
NPI 1922169028
$3,599.73
in general payments reported to CMS, 2019-2025
28 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $103 · 2021: $219 · 2022: $293 · 2023: $852 · 2024: $845 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $511.33 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Glaxosmithkline, LLC. | $466.94 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $290.71 | 2019-2024 | Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $261.27 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.08 | 2022-2025 | |
| Corcept Therapeutics | $228.79 | 2024-2025 | Korlym |
| Urgo Medical North America, LLC | $215.16 | 2023-2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Amgen INC. | $212.27 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $166.26 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $130.65 | 2020-2025 | Ozempic, Rybelsus |
| Smith+Nephew, INC. | $113.58 | 2019-2025 | Collagenase Santyl |
| Xeris Pharmaceuticals, INC. | $113.37 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $110.00 | 2023 | Gemtesa |
| Horizon Therapeutics Plc | $109.99 | 2023 | Krystexxa |
| Astellas Pharma US INC | $99.99 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $42.95 | 2025 | |
| Novartis Pharmaceuticals Corporation | $42.07 | 2019-2021 | |
| Tactile Systems Technology INC | $41.34 | 2019 | |
| Seqirus USA INC | $29.22 | 2019 | |
| Neurocrine Biosciences, INC. | $28.22 | 2024 | Ingrezza |
| Biomarin Pharmaceutical INC. | $26.95 | 2025 | Voxzogo 1.2mg |
| Medtronic, INC. | $22.05 | 2025 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $21.71 | 2025 | Camzyos |
| Misonix INC | $21.46 | 2019 | |
| Hikma Pharmaceuticals USA | $18.25 | 2019 | |
| Pfizer INC. | $14.92 | 2024 | |
| Sunovion Pharmaceuticals INC. | $12.80 | 2020 | |
| Lifenet Health | $6.40 | 2025 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.